RxDoctor Payments Data

Luis Alvarez, NP

Nurse Practitioner · Lyndhurst, NJNPI 1750890323

Payments from drug & device makers

$914in general payments, 2019–2025

Across 45 payments — averaging $20.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$766
  • GSK$88
  • Pfizer$33
  • Johnson & Johnson$27

What the payments were for

  • Food & beverage$914100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca36$766
GSK6$88
Pfizer2$33
Johnson & Johnson1$27

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$914 in reported general payments places this provider in the 75th percentile of 2,138 nurse practitioner providers in New Jersey.

See all nurse practitioner providers in New Jersey

Medicare billing

Part B allowed, 2024
$78,090
Medicare patients
468
Services billed
1,228

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lagevrio (Eua)Molnupiravir19$14,307
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$9,903
Albuterol Sulfate HfaAlbuterol Sulfate215$5,173
PaxlovidNirmatrelvir/Ritonavir56$2,738
Acyclovir20$873
Cephalexin104$785
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav85$741
Azithromycin162$630
Fluticasone Propionate32$507
Ofloxacin13$467
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst31$446
Doxycycline Hyclate43$417
Mupirocin39$316
Prednisone187$290
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip12$219

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBreztri Aerosphere$766$9,90316 claims
PfizerPaxlovid$33$2,73856 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,138 nurse practitioner providers in New Jersey.

Other nurse practitioner in Lyndhurst

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →